Orrick advises Carvolix on EUR 30 Million Structured Debt Financing

Français: Orrick conseille Carvolix dans le cadre de son financement structuré par emprunt de 30 millions d'euros

Carvolix has entered into a structured debt financing transaction for a total amount of up to EUR 30 million, with funds managed by Claret Capital Partners. The financing comprises up to EUR 20 million of senior secured convertible bonds, up to EUR 10 million of senior secured amortized bonds, and warrants.

Orrick advised Carvolix on the structuring and implementation of this transaction.  

THE COMPANY

Carvolix (formerly Affluent Medical) is a French commercial- and clinical-stage medical technology company founded by Truffle Capital. Carvolix specializes in AI-driven mini-robots and biomimetic implants for the treatment of structural heart diseases and strokes.

THE IMPACT

The financing is structured in four tranches, with an immediate initial drawdown of EUR 10 million. The proceeds will support the commercialization of TAVIPILOT in the United States and the advancement of Carvolix's strategic regulatory and clinical developments across its pipeline (TAVIPILOT, Kalios™, Artus, Artedrone, Mitrapilot), as well as general corporate purposes.

THE TEAM

The Orrick team is led by Vianney Toulouse, and includes Alain Decombe and Mathilde Duchamp.

Manaf Triqui and Benjamin Degoul advised from Banking & Finance.